房室结消融联合心脏再同步治疗永久性房颤伴窄QRS患者随机对照试验
该随机对照试验纳入102例永久性房颤(>6个月)、窄QRS(≤110 ms)且既往一年内至少一次心衰住院的严重症状患者,比较房室结消融联合双室起搏(CRT)与药物率控制治疗。中位随访16个月,Ablation+CRT组主要复合终点(心衰死亡、心衰住院或心衰恶化)发生10例(20%),药物组20例(38%),HR 0.38(95%CI 0.18-0.81,P=0.013)。结论:Ablation+CRT优于药物率控制,可减少心衰和住院并改善生活质量。
要点
- 房室结消融联合CRT显著降低主要复合终点风险(HR 0.38)。
- 全因死亡或心衰住院及心衰住院风险均显著降低。
- 1年时房颤特异性症状与躯体限制改善36%。
核心结论
- 在永久性房颤伴窄QRS的老年患者中,房室结消融联合CRT优于药物率控制治疗,可减少心衰和住院并改善生活质量。
研究设计与样本
- 随机对照试验,纳入102例平均年龄72±10岁的永久性房颤(>6个月)、窄QRS(≤110 ms)且既往一年内至少一次心衰住院的严重症状患者,随机分配至房室结消融联合CRT(按指南加除颤器)或药物率控制治疗(按指南加除颤器)。
主要发现
- 中位随访16个月,主要复合终点(心衰死亡、心衰住院或心衰恶化)在Ablation+CRT组发生10例(20%),药物组20例(38%),HR 0.38(95%CI 0.18-0.81,P=0.013)。
- 全因死亡或心衰住院在Ablation+CRT组6例(12%),药物组17例(33%),HR 0.28(95%CI 0.11-0.72,P=0.008)。
- 心衰住院在Ablation+CRT组5例(10%),药物组13例(25%),HR 0.30(95%CI 0.11-0.78,P=0.024)。
- 与药物组相比,Ablation+CRT组1年随访时房颤特异性症状和躯体限制减少36%(P=0.004)。
临床怎么用
- 对于永久性房颤伴窄QRS、严重症状且既往有心衰住院的老年患者,可考虑房室结消融联合CRT以降低心衰住院和死亡风险并改善生活质量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: We tested the hypothesis that atrioventricular (AV) junction ablation in conjunction biventricular pacing [cardiac resynchronization (CRT)] pacing is superior to pharmacological rate-control therapy in reducing heart failure (HF) and hospitalization in patients with permanent atrial fibrillation (AF) and narrow QRS. METHODS AND RESULTS: We randomly assigned 102 patients (mean age 72 ± 10 years) with severely symptomatic permanent AF (>6 months), narrow QRS (≤110 ms), and at least one hospitalization for HF in the previous year to AV junction ablation and CRT (plus defibrillator according to guidelines) or to pharmacological rate-control therapy (plus defibrillator according to guidelines). After a median follow-up of 16 months, the primary composite outcome of death due to HF, or hospitalization due to HF, or worsening HF had occurred in 10 patients (20%) in the Ablation+CRT arm and in 20 patients (38%) in the Drug arm [hazard ratio (HR) 0.38; 95% confidence interval (CI) 0.18-0.81; P = 0.013]. Significantly fewer patients in the Ablation+CRT arm died from any cause or underwent hospitalization for HF [6 (12%) vs. 17 (33%); HR 0.28; 95% CI 0.11-0.72; P = 0.008], or were hospitalized for HF [5 (10%) vs. 13 (25%); HR 0.30; 95% CI 0.11-0.78; P = 0.024]. In comparison with the Drug arm, Ablation+CRT patients showed a 36% decrease in the specific symptoms and physical limitations of AF at 1 year follow-up (P = 0.004). CONCLUSION: Ablation+CRT was superior to pharmacological therapy in reducing HF and hospitalization and improving quality of life in elderly patients with permanent AF and narrow QRS. CLINICALTRIALS.GOV IDENTIFIER: NCT02137187 (May 2018, date last accessed).
引用
- Brignole M, Pokushalov E, Pentimalli F, et al. A randomized controlled trial of atrioventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrial fibrillation and narrow QRS. Eur Heart J. 2018. PMID: 30165479. doi:10.1093/eurheartj/ehy555
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。